Search
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalThe D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.
LI-301
go.drugbank.com/drugs/DB05509ExperimentalLI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … This results in a slight dulling of sensation that can be used to treat premature ejaculation without interfering with normal sexual pleasure or orgasm.
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]
Carbon black
go.drugbank.com/drugs/DB11980InvestigationalProduced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function. … [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416]
Categories: Complex MixturesSynonyms: VEGETABLE CARBON (E 153)Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. S...
Cypermethrin
go.drugbank.com/drugs/DB13721InvestigationalCategories: Compounds used in a research, industrial, or household settingCyfluthrin
go.drugbank.com/drugs/DB13828ExperimentalCategories: Compounds used in a research, industrial, or household settingStevioside
go.drugbank.com/drugs/DB16882InvestigationalCategories: Compounds used in a research, industrial, or household settingDrinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.